ClinicalTrials.govpublic full text
A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma
solid tumor, non-small cell lung cancer recurrent, hepatocellular carcinoma recurrent, interventional, phase1, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 813547
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.